Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PISCES: Pazopanib vs Sunitinib Preference in mRCC
NCT01064310Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of pazopanib in renal cell carcinoma (RCC), sponsored by Novartis. Started May 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01064310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01064310.